Oligodendroglioma
A relatively slow-growing glioma that is derived from oligodendrocytes and tends to occur in the cerebral hemispheres, thalamus, or lateral ventricle. They may present at any age, but are most frequent in the third to fifth decades, with an earlier incidence peak in the first decade. Histologically, these tumors are encapsulated, relatively avascular, and tend to form cysts and microcalcifications. Neoplastic cells tend to have small round nuclei surrounded by unstained nuclei. The tumors may vary from well-differentiated to highly anaplastic forms. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, p2052; Adams et al., Principles of Neurology, 6th ed, p655)
Drugs by status
Approved for this indication (1)
Phase 4 trials (2)
Phase 3 trials (7)
Phase 2 trials (51)
- mannitol
- 131i-tm-601
- mercaptopurine
- abemaciclib
- antineoplaston a10
- bendamustine
- irinotecan
- temsirolimus
- cilengitide
- etirinotecan pegol
- olutasidenib
- imatinib
- lapatinib
- nintedanib
- ritonavir
- Imetelstat
- nivolumab
- tandutinib
- o6-benzylguanine
- okn-007
- palbociclib
- perifosine
- phenylacetic acid
- zarnestra
- resiquimod
- sunitinib
- carboplatin
- lopinavir
- ro4929097
- bevacizumab
- +21 more
Phase 1 trials (64)
- phenobarbital
- plerixafor
- aminolevulinic acid
- azd-8055
- azurin-derived cell-penetrating peptide p28
- urea
- sorafenib
- carboxylesterase-expressing allogeneic neural stem cells
- carcinoembryonic antigen-expressing measles virus
- lenalidomide
- dec-205/ny-eso-1 fusion protein cdx-1401
- doxorubicin
- e. coli cd-expressing genetically modified neural stem cells
- ef5
- fosphenytoin
- gemcitabine
- ima950
- aldesleukin
- cintredekin besudotox
- carbamazepine
- incb7839
- Filgrastim
- pembrolizumab
- lb-100
- ribociclib
- leucovorin
- gadopenteate dimeglumine
- mebendazole
- alisertib
- montanide isa 720
- +34 more
Organizations
Organization Involved with Phase 4 Indications (1)
Organization Involved with Phase 3 Indications (28)
- Shandong Lanjin Pharmaceuticals Co.,Ltd
- Medical Research Council
- National Cancer Institute (NCI)
- Canadian Cancer Trials Group
- Eastern Cooperative Oncology Group
- German Cancer Research Center
- Neuro-Oncology Working Group of the German Cancer Society
- NRG Oncology
- North Central Cancer Treatment Group
- Radiation Therapy Oncology Group
- Southwest Oncology Group
- University of Heidelberg
- University of Toronto
- University of Bonn
- University of Zurich
- University of Leipzig
- Mayo Clinic
- Capital Medical University
- Icahn School of Medicine at Mount Sinai
- European Organisation for Research and Treatment of Cancer
- Sun Yat-Sen University
- University of Duisburg-Essen
- Humboldt University
- University of Duesseldorf
- University of Tuebingen
- Erasmus University Rotterdam
- University of Western Ontario
- The University of Texas, Dallas
Organization Involved with Phase 2 Indications (54)
- Bristol-Myers Squibb
- Schering-Plough
- Merck
- Pfizer
- AEterna Zentaris
- Axelar AB
- AOI Pharmaceuticals, Inc.
- Northwest Biotherapeutics
- Nektar Therapeutics
- Oblato, Inc.
- Teva
- TransMolecular
- Boehringer Ingelheim
- National Institutes of Health (NIH)
- University of Pennsylvania
- Baylor University
- Burzynski Research Institute
- Case Western Reserve University
- Cedars-Sinai Medical Center
- Cornell University
- Harvard University
- Duke University
- Emory University
- University of Washington
- Grupo Español de Investigación en Neurooncología (GEINO)
- Herbert Irving Comprehensive Cancer Center
- Johns Hopkins University
- Medical College of Wisconsin
- Marmara University
- Northwestern University
- +24 more
Organization Involved with Phase 1 Indications (22)
- Millennium Pharmaceuticals
- Pharmacyclics
- Genzyme
- Bayer
- Oncovir, Inc.
- Oncoceutics, Inc.
- Tocagen Inc.
- EpicentRx, Inc.
- University of Pittsburgh
- Cancer and Leukemia Group B (CALGB)
- Thomas Jefferson University
- University of Nebraska
- University of Minnesota
- American Board for Transplant Certification
- City of Hope National Medical Center
- State University of New York, Buffalo
- Insys Therapeutics Inc
- Washington University in St. Louis
- The Andrew McDonough B+ Foundation
- Musella Foundation
- University of Geneva
- St. Jude Children's Hospital
Organization Involved with Other Experimental Indications (4)